Nathan Rice

Stock Analyst at Piper Sandler

(2.75)
# 2,054
Out of 5,057 analysts
60
Total ratings
44.74%
Success rate
7.45%
Average return

Stocks Rated by Nathan Rice

First Mid Bancshares
Nov 3, 2025
Maintains: Overweight
Price Target: $49$48
Current: $37.65
Upside: +27.49%
Merchants Bancorp
Oct 30, 2025
Maintains: Overweight
Price Target: $41$42
Current: $32.50
Upside: +29.23%
Byline Bancorp
Oct 28, 2025
Maintains: Overweight
Price Target: $34$35
Current: $27.50
Upside: +27.27%
Bank First
Oct 23, 2025
Maintains: Neutral
Price Target: $137$142
Current: $125.18
Upside: +13.44%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85$74
Current: $80.26
Upside: -7.80%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $124.70
Upside: -32.64%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $141.69
Upside: +39.04%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11$9
Current: $22.05
Upside: -59.18%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530$435
Current: $713.56
Upside: -39.04%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $270.61
Upside: -13.90%
Initiates: Neutral
Price Target: $83
Current: $36.20
Upside: +129.28%
Initiates: Overweight
Price Target: $15
Current: $18.38
Upside: -18.39%